X-linked Acrogigantism ( X-LAG ) Syndrome : Clinical Profile and Therapeutic Responses
暂无分享,去创建一个
Lim | Jean-François | J. Lupski | F. Faucz | Jacques Young | E. Oldfield | Bonneville | C. Stratakis | N. Pellegata | P. Liu | M. Lodish | M. Jaffrain-Rea | L. Naves | M. Collins | D. Metzger | A. Cotterill | T. Cheetham | A. Philippe | M. Zacharin | L. Rostomyan | A. Beckers | M. Quezado | Bo Yuan | N. Shah | J. Caberg | M. Zatelli | G. Trivellin | E. Castermans | R. Salvatori | S. Zacharieva | A. Daly | P. Chittiboina | S. Neggers | M. Ambrosio | S. Gaillard | C. Choong | C. Villa | G. Barra | Vincent | Lee | P. Petrossians | Pengfei Liu | Elisa | W. D. Herder | B. Santamaría | N. Strebkova | Luís | G. Mantovani | Misu | Verrua | Lysy | N. Mazerkina | Augusto Casulari | E. Mun | Bours
[1] J. Honegger,et al. SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. , 2015, Endocrine-related cancer.
[2] W. D. de Herder. The History of Acromegaly , 2015, Neuroendocrinology.
[3] J. Lupski,et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. , 2014, The New England journal of medicine.
[4] M. Fleseriu,et al. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. , 2014, Journal of molecular endocrinology.
[5] T. Cheetham,et al. Investigation and management of tall stature , 2014, Archives of Disease in Childhood.
[6] C. Stratakis,et al. Carney complex and McCune Albright syndrome: An overview of clinical manifestations and human molecular genetics , 2014, Molecular and Cellular Endocrinology.
[7] S. Melmed,et al. Constitutive Somatostatin Receptor Subtype-3 Signaling Suppresses Growth Hormone Synthesis , 2014, Molecular endocrinology.
[8] P. Chanson,et al. Acromegaly and McCune-Albright syndrome. , 2014, The Journal of clinical endocrinology and metabolism.
[9] V. Esposito,et al. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. , 2013, Endocrine-related cancer.
[10] J. Honegger,et al. Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas , 2013, Acta Neuropathologica.
[11] E. Duncan,et al. Pituitary gigantism treated successfully with the growth hormone receptor antagonist, pegvisomant , 2013, Internal medicine journal.
[12] L. Aaltonen,et al. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. , 2013, Endocrine reviews.
[13] M. Korbonits,et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. , 2012, The Journal of clinical endocrinology and metabolism.
[14] L. Kasuki,et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. , 2012, Endocrine-related cancer.
[15] G. Sassolas,et al. Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery. , 2012, Annales d'endocrinologie.
[16] G. Sassolas,et al. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases. , 2012, The Journal of clinical endocrinology and metabolism.
[17] A. Canalejo,et al. Differential Ontogenetic Patterns of in vitro Desensitization to GHRH in Fetal and Neonatal Anterior Pituitary , 2012, Neuroendocrinology.
[18] A. Iranmanesh,et al. Lifetime Regulation of Growth Hormone (GH) Secretion , 2012 .
[19] N. Bouhours-Nouet,et al. Endocrine Control and Regulation of Growth Hormone: An Overview , 2012 .
[20] M. Junier,et al. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. , 2011, Endocrine-related cancer.
[21] R. Paschke,et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. , 2010, The Journal of clinical endocrinology and metabolism.
[22] M. Rotondi,et al. Prevalence of double pituitary adenomas in a surgical series: Clinical, histological and genetic features , 2010, Journal of endocrinological investigation.
[23] T. Arzberger,et al. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly , 2009, International journal of cancer.
[24] V. Esposito,et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. , 2009, Endocrine-related cancer.
[25] J. Lupski,et al. The DNA replication FoSTeS/MMBIR mechanism can generate genomic, genic and exonic complex rearrangements in humans , 2009, Nature Genetics.
[26] B. Degnan,et al. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. , 2008, The Journal of clinical endocrinology and metabolism.
[27] J. Jane. Management of pediatric sellar tumors. , 2008, Pediatric endocrinology reviews : PER.
[28] J. Lupski,et al. A DNA Replication Mechanism for Generating Nonrecurrent Rearrangements Associated with Genomic Disorders , 2007, Cell.
[29] J. Honegger,et al. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma. , 2006, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[30] P. Laurberg,et al. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. , 2005, European journal of endocrinology.
[31] D. Rubello,et al. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. , 2005, The Journal of clinical endocrinology and metabolism.
[32] I. Lubensky,et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. , 2000, The Journal of clinical endocrinology and metabolism.
[33] F. Gracia‐Navarro,et al. Control of growth hormone secretion from porcine fetal and neonatal pituitary tissue in vitro by growth hormone-releasing hormone, somatostatin, and insulin-like growth factor. , 1997, Neuroendocrinology.
[34] F. Gracia‐Navarro,et al. Different Effects of Somatostatin on in vitro Growth Hormone Release in Two Porcine Breeds with Different Growth Rates 1 , 1996, Journal of neuroendocrinology.
[35] L. Cuttler,et al. Differential desensitization response of the neonatal and adult rat somatotroph to growth hormone-releasing hormone and phorbol ester , 1996, Molecular and Cellular Endocrinology.
[36] J. Itoh,et al. Immunohistochemical characterization of "hyperplasia-adenoma sequence" in the pituitaries of transgenic mice expressing a human growth hormone-releasing factor gene. , 1995, The Tokai journal of experimental and clinical medicine.
[37] S. Asa,et al. Mammosomatotroph adenoma causing gigantism in an 8‐year old boy: a possible pathogenetic mechanism , 1995, Clinical endocrinology.
[38] L. Cuttler,et al. Ontogeny of the GH response to phorbol ester and phospholipase C in rat pituitary cells. , 1995, The Journal of endocrinology.
[39] B. Scheithauer,et al. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation. , 1993, The Journal of clinical endocrinology and metabolism.
[40] P. Marone,et al. The effect of isobutylmethylxanthine, forskolin, and cholera toxin on growth hormone release from pituitary cell cultures of perinatal and mature rats. , 1993, Endocrine research.
[41] S. Asa,et al. Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. , 1992, Endocrinology.
[42] B. Ross,et al. Morphologic effects of hGRH gene expression on the pituitary, liver, and pancreas of MT-hGRH transgenic mice. An in situ hybridization analysis. , 1992, The American journal of pathology.
[43] S. Asa,et al. Gigantism due to pituitary mammosomatotroph hyperplasia. , 1990, The New England journal of medicine.
[44] S. Asa,et al. Pituitary Mammosomatotroph Adenomas Develop in Old Mice Transgenic for Growth Hormone-Releasing Hormone , 1990, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[45] S. Asa,et al. Adenohypophysial changes in mice transgenic for human growth hormone-releasing factor: a histological, immunocytochemical, and electron microscopic investigation. , 1989, Endocrinology.
[46] L. Frohman,et al. Immunohistochemical analysis of human growth hormone-releasing hormone gene expression in transgenic mice. , 1989, Endocrinology.
[47] R. Hammer,et al. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. , 1988, Molecular endocrinology.
[48] R. Hammer,et al. Expression of human growth hormone-releasing factor in transgenic mice results in increased somatic growth , 1985, Nature.
[49] T. Avruskin,et al. Childhood acromegaly: successful therapy with conventional radiation and effects of chlorpromazine on growth hormone and prolactin secretion. , 1973, The Journal of clinical endocrinology and metabolism.
[50] S. Raiti,et al. Acromegaly in a 9 and one-half-year-old boy. Pituitary function studies before and after surgery. , 1972, American journal of diseases of children.
[51] L. M. Hurxthal. Pituitary gigantism in a child five years of age: effect of x-radiation, estrogen therapy and self-imposed starvation diet during an eleven-year period. , 1961, The Journal of clinical endocrinology and metabolism.
[52] A. Oñativia,et al. Acromegaly and gigantism in a boy: comparison with 3 overgrown nonacromegalic children , 1960 .
[53] Todd Rm. Acromegaly in a girl of 8 years. , 1958 .